Advanced Fibrosis Detection for MASLD in Primary Care
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMedical University of South Carolina
About this trial
This proposal evaluates the implementation of a novel, non-interruptive, electronic health record alert for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis risk assessment in primary care patients with MASLD using a stepped wedge, cluster randomized design. This work will generate generalizable data to dramatically enhance MASLD management in primary care.
Eligibility criteria
Qualifiers
Patients with a diagnosis code for MASLD
Type 2 diabetes mellitus will
Disqualifiers
All patients with cirrhosis, complications of cirrhosis (e.g. portal hypertension, hepatic encephalopathy), hepatocellular carcinoma, or previous liver transplant will be excluded.
pregnant women.
Trial design
Treatments tested in this trial
- EHR alert
Treatment groups
225 Participants
are divided into 5 treatment groupsSponsors and collaborators
Medical University of South Carolina
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
National Institutes of Health (NIH)
Collaborator
Source ClinicalTrials.gov